Mexico.- The Federal Commission for the Protection Against Sanitary Risks (Cofepris) authorized the use of the drug siponimod, intended for the treatment of people with multiple sclerosis, which helps delay the disability caused by the disease.
It was on December 10, 2021, when the technical agencies of the federal agency gave their approval to the treatment developed by the company Novartis, which is indicated for elderly patients with secondary progressive multiple sclerosis.
Siponimod is an immunomodulatory therapy endorsed for the treatment of secondary progressive multiple sclerosis, since it helps to delay the process of disability progression, thereby reducing the action of immune cells that can cause nerve damage.
Read more: Immunity in February! They affirm that ‘half Mexico’ will contract Covid in 2 weeks
The results of the phase 3 study that was carried out before its approval, showed that this new treatment can delay up to 4.3 years the use of wheelchairs in patients suffering from this degenerative disease.
At present, it is estimated that around 20 thousand people in Mexico between 20 and 35 years of age suffer from multiple sclerosis. The main symptoms of this disease are lack of sensation, involuntary shaking, tingling, stiffness, difficulty in maintaining balance, and tight muscles. Although there is no cure for multiple sclerosis, there are treatments focused on improving the quality of life of people who suffer from it.
Cofepris authorizes oral medication to treat Covid-19
Last week, the Federal Commission for the Protection against Sanitary Risks approved the emergency use of oral treatment molnupiravir for patients with Covid-19 who have mild or moderate symptoms of the disease and who have at least one risk factor that could aggravate their health.
Read more: Omicron infection is not a flu: PAHO
“Based on the available studies, Cofepris determined that this treatment may be authorized for emergency use under the therapeutic indication: treatment of mild to moderate COVID-19 disease in adults with a positive SARS-cov-2 diagnostic test, which does not require supplemental oxygen, for those who have at least one risk factor for developing severe COVID-19 including hospitalization or death and for whom the authorized alternative COVID-19 treatment options are not accessible or clinically appropriate, “the agency said in a statement. .